Ryaltris

— THERAPEUTIC CATEGORIES —
  • Rhinitis/rhinorrhea (intranasal products)

Ryaltris Generic Name & Formulations

General Description

Olopatadine (as HCl) 665mcg, mometasone (as furoate monohydrate) 25mcg; per nasal spray.

Pharmacological Class

Antihistamine + corticosteroid.

How Supplied

Spray—29g (240 sprays)

Generic Availability

NO

Ryaltris Indications

Indications

Seasonal allergic rhinitis.

Ryaltris Dosage and Administration

Adult

Use 2 sprays in each nostril twice daily.

Children

<12yrs: not established.

Ryaltris Contraindications

Not Applicable

Ryaltris Boxed Warnings

Not Applicable

Ryaltris Warnings/Precautions

Warnings/Precautions

Risk of epistaxis, nasal ulcerations, nasal septal perforations, impaired nasal wound healing, local Candida infections; monitor periodically. Recent nasal septal ulcers, nasal surgery, or nasal trauma: avoid until healing has occurred. Discontinue if Candida infections or hypersensitivity reactions occur. Monitor closely if change in vision or those with a history of increased intraocular pressure, glaucoma, and/or cataracts. Immunosuppression. Respiratory tract tuberculosis. Infections (eg, fungal, bacterial, viral, ocular herpes simplex). If exposed to measles or chickenpox, may need immunoglobulin or VZIG prophylactic therapy. Hypercorticism. Adrenal suppression. Monitor routinely for growth in children. Hepatic impairment. Pregnancy. Nursing mothers.

Ryaltris Pharmacokinetics

Metabolism

Olopatadine is not extensively metabolized.

Elimination

Olopatadine: renal (~70%), fecal (~17%).  Half-life: 9 hours (olopatadine); 18 hours (mometasone furoate).

Ryaltris Interactions

Interactions

Avoid concomitant alcohol or other CNS depressants. Caution with strong CYP3A4 inhibitors (eg, ketoconazole).

Ryaltris Adverse Reactions

Adverse Reactions

Dysgeusia, epistaxis, nasal discomfort; somnolence, impaired mental alertness.

Ryaltris Clinical Trials

See Literature

Ryaltris Note

Not Applicable

Ryaltris Patient Counseling

See Literature